Lipaglyn Tablet contains Saroglitazar 4 mg, an oral dual PPAR α/γ agonist indicated for the management of diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus not adequately controlled by statins alone. Saroglitazar acts by modulating lipid and glucose metabolism through activation of peroxisome proliferator-activated receptors (PPARs), leading to improved insulin sensitivity, reduction in triglycerides, and favorable effects on LDL and HDL cholesterol levels. It is primarily prescribed to reduce cardiovascular risk factors associated with diabetes by addressing both glycemic control and lipid abnormalities. Lipaglyn is administered once daily, with or without food, and dosage adjustments should be based on clinical response and tolerability. Common adverse effects may include mild gastrointestinal disturbances, headache, and transient elevation of liver enzymes; however, it is generally well tolerated. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision with regular monitoring of lipid profile, liver function tests, and glycemic parameters. Lipaglyn Tablet represents an important therapeutic option for comprehensive metabolic control in type 2 diabetes patients with dyslipidemia, contributing to improved cardiovascular outcomes when used as part of a multifactorial treatment approach.